Long-Term Effects of Iloperidone on Cerebral Serotonin and Adrenoceptor Subtypes

Journal of Molecular Neuroscience

Volumn 66, Issue 1, 2018, Pages 59-67

  Choi, Yong Kee ^a,b   Tarazi, Frank I ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Adrenoceptors; Antipsychotic drugs; Iloperidone; Schizophrenia; Serotonin receptors

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ASENAPINE; ILOPERIDONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; ALPHA ADRENERGIC RECEPTOR; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; DORSAL STRIATUM; DORSOLATERAL PREFRONTAL CORTEX; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; FOREBRAIN; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; MALE; MEDIAL PREFRONTAL CORTEX; NEGATIVE SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; RAT; RECEPTOR AFFINITY; REPEATED DRUG DOSE; ANIMAL; BASAL GANGLION; BRAIN CORTEX; GENETICS; HIPPOCAMPUS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; CEREBRAL CORTEX; HIPPOCAMPUS; ISOXAZOLES; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA;

EID: 85051547283     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-018-1133-z     Document Type: Article

References (57)

1. Amargós-Bosch M, Adell A, Bortolozzi A, Artigas F (2003) Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J Neurochem 87(4):831–842
2. Arif SA, Mitchell MM (2011) Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm 68(4):301–308
3. Arnsten AF (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 174:25–31
4. Baldessarini RJ, Frankenburg FR (1991) Clozapine–a novel antipsychotic agent. N Engl J Med 324:746–754
5. Baldessarini RJ, Tarazi FI (2005) Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker K (eds) Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 461–500
6. Barr AM, Powell SB, Markou A, Geyer MA (2006) Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51:457–465
7. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the action mechanism of clozapine. Neuropsychopharmacology 13:177–213
8. Cahir M, Mawhinney T, King DJ (2004) Differential region-specific regulation of central alpha 1-adrenoceptor binding following chronic haloperidol and clozapine administration in the rat. Psychopharmacology 172:196–201
9. Choi YK, Tarazi FI (2018) Long-term effects of iloperidone on cerebral dopamine receptor subtypes. Synapse. 10.1002/syn.22039
10. Choi YK, Wong EH, Henry B, Shahid M, Tarazi FI (2010) Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 13:405–410
11. Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI (2017) Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectr 22(6):484–494
12. Corbett R, Griffiths L, Shipley JE, Shukla U, Strupczewskim JT, Szczepanik AM, Szewczak MR, Turk DJ, Vargas HM, Kongsamut S (1997) Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev 3(2):120–147
13. Deng C, Dean B (2013) Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathways. Front Cell Neurosci 7:238
14. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25:10831–10843
15. Florijn WJ, Tarazi FI, Creese I (1997) Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280(2):561–569
16. Francis PT, Pangalos MN, Pearson RC, Middlemiss DN, Stratmann GC, Bowen DM (1992) 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther 261(3):1273–1281
17. Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56:615–649
18. Greene WH (2000) Econometric analysis, 4th edn. Prentice Hall, Upper Saddle River, pp 462–465
19. Gundlach AL, Burazin TC, Jenkins TA, Berkovic SF (1995) Spatiotemporal alterations of central alpha 1-adrenergic receptor binding sites following amygdaloid kindling seizures in the rat: autoradiographic studies using [3H]prazosin. Brain Res 672:214–227
20. Gurevich EV, Joyce JN (1997) Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42:529–545
21. Happe HK, Coulter CL, Gerety ME, Sanders JD, O’Rourke M, Bylund DB, Murrin LC (2004) Alpha-2 adrenergic receptor development in rat CNS: an autoradiographic study. Neuroscience 123:167–178
22. 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112:S35–S39
23. Heckers S, Konradi C (2015) GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res 167(1–3):4–11
24. 2 adrenoceptor blockade. Science 286:105–107
25. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521–1531
26. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, Mark S, Lieberman JA, Javitch JA (2010) Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 31(8):381–390
27. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 317:417–423
28. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 50:810–818
29. Leucht S (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41
30. 2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 13(7):891–903
31. 2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367:197–206
32. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393–406
33. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1159–1172
34. 1A receptors. J Pharmacol Exp Ther 295(3):853–861
35. 1 adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. Neuropsychopharmacology 37:2161–2172
36. Ninan I, Jardemark KE, Wang RY (2003) Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48(2):66–79
37. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol 8(4):193–195
38. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. 2nd edn. Academic, Cambridge
39. Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346(2):205–230
40. 1A receptor in the rat brain: correlation with receptor binding. J Neurosci 12:440–453
41. Pudovkina OL, Westerink BH (2005) Functional role of alpha1-adrenoceptors in the locus coeruleus: a microdialysis study. Brain Res 1061:50–56
42. Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17–24
43. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124(1–2):57–73
44. Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23(1):65–73
45. 1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr 18:285–288
46. 2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem 38:1119–1131
47. Svensson TH (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1145–1158
48. Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M (1995) The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 274(3):1404–1413
49. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (2005) Alpha1-adrenoreceptor in human hippocampus: binding and receptor subtype mRNA expression. Mol Brain Res 139(2):367–371
50. Tarazi FI, Stahl SM (2012) Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 13(13):1911–1922
51. Tarazi FI, Zhang K, Baldessarini RJ (2002) Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 161(3):263–270
52. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M (2010) Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 24(3):341–348
53. Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16(1):23–45
54. Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R (2016) Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evid 11:49–61
55. 2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191–202
56. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD (2008) Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 28(2 Suppl 1):S12–S19
57. Winer BJ, Brown DR, Michels KM (1991) Statistical principles in experimental drug design, 3rd edn. McGraw-Hill, New York, pp 165–166